NEW YORK, April 04, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased CEMEX, S.A.B. de C.V. ("CEMEX") (NYSE:CX) securities between August 14, 2014 and March 13, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/cemex?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) CEMEX executives had engaged in an unlawful bribery scheme in connection with the Company’s business dealings in Colombia; (ii) discovery of the foregoing conduct would likely subject the Company to heightened regulatory scrutiny and potential criminal sanctions; (iii) the Company lacked adequate internal controls over financial reporting; and (iv) as a result, CEMEX's public statements were materially false and misleading at all relevant times.
If you suffered a loss in CEMEX you have until May 15, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/cemex?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]


Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Honda, Nissan Eye Shared Vehicle Software Platform by 2029
PayPal Shares Sink as $50 Billion Takeover Bid Collapses
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Toyota Global Sales Fall as China Demand Slumps
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns
Google Changes EU Spam Policy Amid Antitrust Scrutiny
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 



